Docetaxel
About
Therapy type: Chemotherapy
Therapy strategy: Taxane-based chemotherapy
Mappings
NCI Thesaurus: Docetaxel (coding:ncit:C1526)
RxNorm: docetaxel (coding:rxcui:72962, coding:omop:4305104)
SNOMED: Docetaxel (coding:sctid:386918005, coding:omop:1315942)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) HC (5) | HER2-positive | Invasive Breast Carcinoma | Docetaxel, Pertuzumab, Trastuzumab | |
| FDA (4) HC (2) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab | |
| FDA (2) HC (2) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab | |
| FDA (2) HC (2) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab | |
| FDA (2) HC (2) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab | |
| FDA (2) HC (2) | HER2-positive | Invasive Breast Carcinoma | Carboplatin, Docetaxel, Pertuzumab, Trastuzumab | |
| HC (1) | HER2-positive | Invasive Breast Carcinoma | Carboplatin, Docetaxel, Trastuzumab | |
| HC (1) | HER2-positive | Invasive Breast Carcinoma | Docetaxel, Paclitaxel, Trastuzumab |